AMEX · Biotechnology

NRXS (NRXS) Stock

$6.53 -3.12% AMEX: NRXS Healthcare

Valuation

MetricValue
Price$6.53
Market Cap$80.87M
P/E Ratio-116.50
P/B Ratio13.92
P/S Ratio19.90
EPS (TTM)$-0.03
52-Week High$9.33
52-Week Low$2.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-242.53%
ROA-77.11%
ROCE-266.67%
Gross Margin85.01%
Operating Margin-1.70%
Net Margin-1.70%
Debt/Equity0.06
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$3.0M$2.0M$3.0M$4.0M
Operating Profit$-3.0M$-3.0M$-7.0M$-7.0M$-8.0M
Net Profit$-3.0M$-5.0M$-15.0M$-8.0M$-8.0M
EPS$-0.62$-0.78$-2.32$-1.22$-0.95
Op Margin-109.1%-125.6%-270.9%-266.5%-219.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$1.0M$1.0M$5.0M$6.0M
Total Liabilities$2.0M$7.0M$2.0M$3.0M$3.0M
Cash$0$0$0$4.0M$5.0M
Borrowings$0$1.0M$0$0$0

Latest News

NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum Insider Monkey · May 18, 2026 NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y Zacks · May 15, 2026 Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges GuruFocus.com · May 12, 2026 NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth GlobeNewswire · May 12, 2026 Earnings To Watch: Neuraxis Inc (NRXS) Reports Q1 2026 Result GuruFocus.com · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-2.0M$-7.0M$-6.0M$-6.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$-1.0M$-1.0M$0$0$-1.0M
Net Cash Flow$-2.0M$0$0$4.0M$1.0M
Free Cash Flow$-2.0M$-2.0M$-7.0M$-6.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-2177.44
EV / EBITDA-10.60
FCF Yield-7.13%
Quick Ratio2.81
Interest Coverage—
Return 1Y185.13%
Return 3Y—
Return 5Y—

Ownership

Insiders Held19.82%
Institutions Held22.75%
Institutions Float Held28.37%
Institutional HolderSharesReport Date
AIGH Capital Management LLC400,0002026-03-31
Rosalind Advisors, Inc.286,1382026-03-31
Money Concepts Capital Corporation225,5552026-03-31
Vanguard Capital Management LLC225,8672026-03-31
Panoramic Capital, LLC 190,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLGN $0.27 -9.04% -0.48 $3.54M 0.00%
CVKD $2.06 +0.98% -0.78 $6.38M 0.00%
ENLV $2.12 -5.36% 0.03 $35.68M 0.00%
KLTOKlotho Neurosciences, Inc. $0.38 -7.10% -1.13 $20.08M 0.00%
NERVMinerva Neurosciences, Inc. $4.14 +2.35% -0.14 $28.92M 0.00%

About NRXS

NRXS is led by CEO Brian Carrico, employs 21 people, headquartered in US, publicly traded since 2023.

NRXS stock trades at $6.53 with a market capitalization of $80.87M. The stock is valued at a price-to-earnings (P/E) ratio of -116.50, price-to-book of 13.92, price-to-sales of 19.90. Over the past 52 weeks the stock has ranged between $2.20 and $9.33, and currently trades 30.0% below its 52-week high.

On profitability, NRXS generates a return on equity (ROE) of -242.53%, return on capital employed of -266.67%, an operating margin of -1.70%, a net profit margin of -1.70%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides